Shopping Cart 0
Cart Subtotal
AED 0

Rhino-Conjunctivitis-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Rhino-Conjunctivitis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis-Pipeline Review, H2 2017, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 9, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rhino-Conjunctivitis-Overview

Rhino-Conjunctivitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rhino-Conjunctivitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rhino-Conjunctivitis-Companies Involved in Therapeutics Development

ALK-Abello AS

Allergopharma GmbH & Co KG

Allergy Therapeutics Plc

ASIT Biotech SA

Astellas Pharma Inc

Bial-Portela & Ca SA

Faes Farma SA

Griffin Discoveries BV

HAL Allergy BV

Laboratorios LETI SL

Oxagen Ltd

Rhino-Conjunctivitis-Drug Profiles

Acaroid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergovac-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4070-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-41-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gp-ASIT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hdm-ASIT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OC-2417-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Birch-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Grass-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Timapiprant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rhino-Conjunctivitis-Dormant Projects

Rhino-Conjunctivitis-Discontinued Products

Rhino-Conjunctivitis-Product Development Milestones

Featured News & Press Releases

Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial

May 30, 2017: ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+ at EAACI

Nov 30, 2015: Allergy Therapeutics Completes Patient Enrolment For Birch Study

May 18, 2014: BioTech Tools will be present at the EAACI congress

Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet

Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics

Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites

Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil

Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA

Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study

Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain

Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries

Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Rhino-Conjunctivitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Rhino-Conjunctivitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Rhino-Conjunctivitis-Pipeline by ALK-Abello AS, H2 2017

Rhino-Conjunctivitis-Pipeline by Allergopharma GmbH & Co KG, H2 2017

Rhino-Conjunctivitis-Pipeline by Allergy Therapeutics Plc, H2 2017

Rhino-Conjunctivitis-Pipeline by ASIT Biotech SA, H2 2017

Rhino-Conjunctivitis-Pipeline by Astellas Pharma Inc, H2 2017

Rhino-Conjunctivitis-Pipeline by Bial-Portela & Ca SA, H2 2017

Rhino-Conjunctivitis-Pipeline by Faes Farma SA, H2 2017

Rhino-Conjunctivitis-Pipeline by Griffin Discoveries BV, H2 2017

Rhino-Conjunctivitis-Pipeline by HAL Allergy BV, H2 2017

Rhino-Conjunctivitis-Pipeline by Laboratorios LETI SL, H2 2017

Rhino-Conjunctivitis-Pipeline by Oxagen Ltd, H2 2017

Rhino-Conjunctivitis-Dormant Projects, H2 2017

Rhino-Conjunctivitis-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

ALK-Abello AS

Allergopharma GmbH & Co KG

Allergy Therapeutics Plc

ASIT Biotech SA

Astellas Pharma Inc

Bial-Portela & Ca SA

Faes Farma SA

Griffin Discoveries BV

HAL Allergy BV

Laboratorios LETI SL

Oxagen Ltd

Rhino-Conjunctivitis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis-Pipeline Review, H2 2017, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 9, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rhino-Conjunctivitis-Overview

Rhino-Conjunctivitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rhino-Conjunctivitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rhino-Conjunctivitis-Companies Involved in Therapeutics Development

ALK-Abello AS

Allergopharma GmbH & Co KG

Allergy Therapeutics Plc

ASIT Biotech SA

Astellas Pharma Inc

Bial-Portela & Ca SA

Faes Farma SA

Griffin Discoveries BV

HAL Allergy BV

Laboratorios LETI SL

Oxagen Ltd

Rhino-Conjunctivitis-Drug Profiles

Acaroid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergovac-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4070-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-41-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gp-ASIT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hdm-ASIT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OC-2417-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Birch-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Grass-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Timapiprant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rhino-Conjunctivitis-Dormant Projects

Rhino-Conjunctivitis-Discontinued Products

Rhino-Conjunctivitis-Product Development Milestones

Featured News & Press Releases

Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial

May 30, 2017: ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+ at EAACI

Nov 30, 2015: Allergy Therapeutics Completes Patient Enrolment For Birch Study

May 18, 2014: BioTech Tools will be present at the EAACI congress

Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet

Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics

Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites

Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil

Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA

Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study

Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain

Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries

Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Rhino-Conjunctivitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Rhino-Conjunctivitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Rhino-Conjunctivitis-Pipeline by ALK-Abello AS, H2 2017

Rhino-Conjunctivitis-Pipeline by Allergopharma GmbH & Co KG, H2 2017

Rhino-Conjunctivitis-Pipeline by Allergy Therapeutics Plc, H2 2017

Rhino-Conjunctivitis-Pipeline by ASIT Biotech SA, H2 2017

Rhino-Conjunctivitis-Pipeline by Astellas Pharma Inc, H2 2017

Rhino-Conjunctivitis-Pipeline by Bial-Portela & Ca SA, H2 2017

Rhino-Conjunctivitis-Pipeline by Faes Farma SA, H2 2017

Rhino-Conjunctivitis-Pipeline by Griffin Discoveries BV, H2 2017

Rhino-Conjunctivitis-Pipeline by HAL Allergy BV, H2 2017

Rhino-Conjunctivitis-Pipeline by Laboratorios LETI SL, H2 2017

Rhino-Conjunctivitis-Pipeline by Oxagen Ltd, H2 2017

Rhino-Conjunctivitis-Dormant Projects, H2 2017

Rhino-Conjunctivitis-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

ALK-Abello AS

Allergopharma GmbH & Co KG

Allergy Therapeutics Plc

ASIT Biotech SA

Astellas Pharma Inc

Bial-Portela & Ca SA

Faes Farma SA

Griffin Discoveries BV

HAL Allergy BV

Laboratorios LETI SL

Oxagen Ltd

chat_bubbleLet's Chat